Last updated 2026-09-06
- Went public on NASDAQ (MDWD), Mar 2014
- Raised $125M Public Offering, Mar 2025
- Raised $30M Public Offering, Sep 2025
Total raised
$372.5M
Last: Grant 2024-07
Stage
Public
Founded
2000
Headcount
123
HQ
Yavne, Israel
Sector
Health Tech & Life Sciences
About
MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics for non-surgical tissue repair. Its solutions selectively remove non-viable hazardous tissue while preserving healthy tissue, offering a safer and more effective alternative to traditional methods. With robust in-house research, development, and manufacturing capabilities, the company produces and commercializes cutting-edge biologics for wound and burn care that exceed existing standards of care, improve patient outcomes, and reduce healthcare costs by eliminating the need for surgical interventions. MediWound’s flagship product, NexoBrid, is an FDA, EMA and PMDA approved orphan designated biologic, currently in use worldwide for treating severe burns. Building on its proprietary enzymatic technology, MediWound is advancing EscharEx, a promising Phase III pipeline drug for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
Funding history · 13 rounds · $372.5M total
15 events/rounds · $372.5M Total Funding: $20.0M in Private Equity, $442.7M in Public Equity, $6.8M in Debt
Sep 2025
Public Offering
$30.0M
EDGAR filing SEC-EDGAR 424B5
Mar 2025
Public Offering
$125.0M
EDGAR filing SEC-EDGAR 424B3
Sep 2024
Public Offering
$25.0M
EDGAR filing SEC-EDGAR 424B3
Apr 2023
Public Offering
$35.5M
EDGAR filing SEC-EDGAR 424B3
Sep 2022
Public Offering
$13.3M
EDGAR filing SEC-EDGAR 424B5
Mar 2022
Public Offering
$10.0M
EDGAR filing SEC-EDGAR 424B5
Feb 2020
Public Offering
$15.0M
EDGAR filing SEC-EDGAR 424B5
Sep 2017
Public Offering
$22.0M
EDGAR filing SEC-EDGAR 424B5
Mar 2014
Public Offering
$70.0M
EDGAR filing SEC-EDGAR 424B4
Aug 2013
Rights Offering
$20.0M
globes.co.il
★ Arte★ Leor Rosenberg★ Israeli institutions★ Mölnlycke Health Care★ financial institutions★ Clal Biotechnology Industries★ several Israeli investment institutions★ Migdal Insurance and Financial Holdings Ltd.Point72Sol J. BarerYair Schindel1 angel investorClal Biotechnologyother current shareholdersother financial institutionsSeven global financial institutionsEuropean Innovation Council (EIC) Accelerator programHarel Insurance Investments and Financial Services Ltd.
Dec 2012
Convertible Debt
$6.8M
calcalist.co.il
★ Teva Pharmaceutical Industries Ltd.
2010
A Round
Undisclosed
calcalist.co.il
★ PolyHeal Ltd.★ Teva Pharmaceutical Industries Ltd.
2000
Seed
Undisclosed
dealroom.co
★ Ben-Gurion University of the Negev
Headcount over time
123 employees (2026-09) · 1 point
Offices
Yavne, Israel · HQ / main office
Show all offices (2 more)
- Wilmington, United States
- Rüsselsheim, Germany
Q&A
- What is MediWound's primary focus?
- MediWound is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair.
- What is NexoBrid® and where is it marketed?
- NexoBrid® is MediWound's FDA-approved biologic indicated for the enzymatic removal of eschar in thermal burns. It is marketed in the U.S., European Union, Japan, and other international markets.
- What is MediWound's current stage of development for EscharEx®?
- EscharEx® is a late-stage investigational therapy for the debridement of chronic wounds.
- When did MediWound become a public company?
- MediWound became public on NASDAQ in March 2014, with an IPO of $75,000,000 at a valuation of $400,000,000.
- What was MediWound's most recent funding round?
- In July 2024, MediWound received a Grant of $2,500,000.
- What was a significant recent development for NexoBrid®?
- In August 2024, MediWound announced U.S. Food and Drug Administration approval of NexoBrid® for the treatment of pediatric patients with severe thermal burns.
- What is the status of MediWound's manufacturing facility for NexoBrid®?
- In November 2025, MediWound successfully completed the commissioning of its expanded GMP manufacturing facility for NexoBrid®.
- What is MediWound's current employee count?
- MediWound has 51-200 employees.
- What is MediWound's market capitalization?
- MediWound's market capitalization is $236,683,653.
Team · 16
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Highlights
1 Patents
Tags
tissue-regenerationdermatologyburnsbiotechnologytopical-treatmentpatientspharma-companiespharmaceuticals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | mediwound.com |
|---|---|
| linkedin.com/company/1644054 | |
| facebook.com/pages/Mediwound/457872115038886 | |
| YouTube | youtube.com/user/MediWound |
| Wikidata | wikidata.org/wiki/Q43896231 |
Identifiers & details
| Legal name | MediWound Ltd. |
|---|---|
| Founded | 2000-1 |
| Employees (exact) | 123 |
| Offices | Wilmington; Rüsselsheim |
| Market cap | $236.7M |
| Status reason | Public on NASDAQ on Mar, 2014; |
| Wikidata QID | Q43896231 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2014-03 | NASDAQ | MDWD | $75.0M |
| Public Offering | 2017-06 | NASDAQ | $22.0M |
Radar intelligence
Patents
| EPO | 14 |
|---|
Publications (Crossref)
| Works | 5 |
|---|
Web history (Wayback)
| Domain | mediwound.com |
|---|
Wikidata
| QID | Q43896231 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 512894940 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 2000-01-27 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2022 |
| Active charges / liens | 0 |
| Registry events | 1 — charge (1) |
| Registered address | הירקון 42 יבנה |
Recent registry events
| Date | Event |
|---|---|
| 2026-08-12 | עדכון שעבוד |